glioblastoma

[iScience] Researchers investigated Smurf1 expression in various glioblastoma (GB) cell lines and patient tissues and found Smurf1 loss elevated PTEN levels that interrupted the epidermal growth factor receptor pathway activity.

[NOXXON Pharma N.V.] NOXXON Pharma N.V. announced that the first patient was enrolled in an expansion arm of the GLORIA clinical trial of NOX-A12 in MGMT unmethylated brain cancer.

[Photodiagnosis and Photodynamic Therapy] Scientists present a brief review exclusively commenting on the therapeutic approaches to eliminate glioblastoma stem cells and on the research publications about this topic of glioblastoma stem cells in relation to photodynamic therapy.

[Oncotelic Therapeutics, Inc.] Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.

[Tissue Engineering Part A] Scientists observed spatially heterogeneous GBM cell populations emerged from an isogenic clonal population of glioma-initiating cells during invasion into a 3D collagen hydrogel in a microfluidic device.

[Cytovia Therapeutics, Inc. (GlobeNewswire, Inc.)] Cytovia Therapeutics, Inc. and Cellectis announced that they have expanded their collaboration of TALEN® gene-edited iPSC-derived natural killer (NK) and chimeric antigen receptor (CAR)-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.